



Personal Genome Diagnostics Appoints Megan Bailey as Chief Commercial Officer

— Industry veteran to drive global commercialization of cancer genomics product line —

BALTIMORE, MD, January 28, 2020 – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today appointed Megan Bailey as Chief Commercial Officer (CCO). A seventeen-year veteran of the health diagnostics industry, Bailey joined PGDx in March of 2018 as the Vice President of Marketing. As CCO, Megan will lead marketing, sales, customer support, and communications in developing and executing global go-to-market strategies to empower the fight against cancer.

“Megan’s track record of leadership and impact speaks for itself, as she has been a key driving force behind the evolution and growth of PGDx,” said Douglas Ward, Chief Executive Officer, PGDx. “This is an incredibly exciting time for our company as we prepare for an upcoming FDA clearance. Megan’s broad experience will be tremendously valuable as we continue advancing our strategic commercialization plans and best practices for delivering precision medicine to more oncology patients globally.”

Bailey has been instrumental in advancing the PGDx vision to fundamentally change oncology care by delivering products that enable local precision medicine, including the securing of CE marks for both the elio™ tissue complete assay and elio™ plasma resolve. In an effort to gather valuable feedback on the robustness and performance of PGDx assays, Bailey has also played a key role in establishing strategic collaborations with organizations such as the Mayo Clinic and PathGroup.

“Genomics is the fastest-growing field of molecular diagnostics and I’m inspired on a daily basis by our team’s inherent desire to change the standard of care in oncology by enabling the delivery of deeper clinical insights,” said Bailey. “I am so proud to be part of PGDx and to take on this new role as we continue our purpose-driven focus on patient impact and being a catalyst for real change in the fight against cancer.”

Prior to joining PGDx, Bailey spent more than 14 years at Roche, primarily in sales and marketing leadership roles. Most recently as Senior Director of Commercial Operations, Bailey led a sales organization responsible for a diagnostics portfolio that included Clinical Chemistry, Molecular Diagnostics, Point of Care and Tissue Diagnostics.

Bailey earned a bachelor’s degree in English with a minor in Systems Engineering from the United States Military Academy at West Point and a master’s degree in Public Health from the University of North Carolina – Chapel Hill.

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.PersonalGenome.com.

###

Contact:

W2O Group:
Karl Stetson
206-445-7506
kstetson@w2ogroup.com